Related Experiment Video

Updated: May 30, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Non-congenital heart disease associated pediatric pulmonary arterial hypertension

D D Ivy1, J A Feinstein, T Humpl

  • 1University of Colorado Denver School of Medicine and The Children's Hospital, United States.

Progress in Pediatric Cardiology
|September 28, 2011
PubMed

Insights

Identifying and treating pediatric pulmonary hypertension causes beyond congenital heart disease is vital. This review explores various conditions and adult-tested medications, highlighting the need for more pediatric research.

Area of Science:

  • Pediatric Cardiology
  • Pulmonology
  • Medical Research

Background:

  • Pulmonary hypertension (PH) in children is increasingly recognized beyond congenital heart disease.
  • Accurate diagnosis and management of underlying causes are essential for optimal PH treatment in pediatric patients.

Purpose of the Study:

  • To review current knowledge on pediatric disorders associated with pulmonary hypertension.
  • To discuss the use of adult-tested PH medications in children, including prostanoids, endothelin receptor antagonists, and phosphodiesterase inhibitors.

Main Methods:

  • Literature review of pediatric pulmonary hypertension causes.
  • Analysis of drug classes used in adult idiopathic pulmonary arterial hypertension (IPAH) treatment.
  • Examination of medication use in pediatric pulmonary arterial hypertension (PAH).

Main Results:

  • Several non-congenital heart disease causes of pediatric PH are identified, including IPAH, pulmonary capillary hemangiomatosis, and hepatopulmonary syndrome.
  • Medications like prostanoids, endothelin receptor antagonists, and phosphodiesterase inhibitors are used in children with PAH, mirroring adult treatments.
  • Limited randomized clinical trial data exists for these treatments in pediatric populations.

Conclusions:

  • Further research is crucial to establish the safety and efficacy of pulmonary vasodilator therapies in children with PH.
  • Careful consideration and further study are needed before widespread adoption of these medications in pediatric PH management.
  • Understanding diverse PH etiologies in children is key to guiding appropriate therapeutic strategies.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Edema II: Pathophysiology01:18

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...